<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092597</url>
  </required_header>
  <id_info>
    <org_study_id>HEALTH-282521-CUNI</org_study_id>
    <nct_id>NCT02092597</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Adverse Reactions in Diabetes</brief_title>
  <acronym>SAFEGUARD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of incretin-based antidiabetic therapies
      (DPP-4 inhibitors and GLP-1 agonists) on cardiovascular, gastrointestinal and renal system
      and to detail the mechanisms underlying their action in these systems.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric evacuation velocity</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intimomedial thickness</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tubular function</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>KIM-1</measure>
    <time_frame>90 days after treatment initiation</time_frame>
    <description>Marker of renal damage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exocrine pancreas function</measure>
    <time_frame>90 days after treatment initiation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>GLP-1 agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exenatide 5 ug s.c. bid for the 1st month, 10 ug s.c. bid for the next 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Linagliptin 5 mg tbl qd for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea derivate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gliclazid 30 mg tbl qd for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <arm_group_label>GLP-1 agonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
    <arm_group_label>Sulfonylurea derivate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Metformin monotherapy - stable dose during last 3 months

          -  HbA1C 48-75 mmol/mol (IFCC)

          -  BMI 25-40 kg/m2

          -  Age 35-70 years (women postmenopausal)

          -  Use of ACE inhibitors or ATII receptor blockers for at least 3 months before
             enrollment

        Exclusion Criteria:

          -  eGFR&lt;30 ml/min/1.73m2 (MDRD)

          -  Treatment with incretin mimetics during 3 months before enrollment

          -  Chronic insulin therapy

          -  Chronic use of loop diuretics, glucocorticoids, NSAID, immune suppressants,
             antimicrobial agents, chemotherapeutics, bile acid sequestrants (colestyramin,
             colesevelam)

          -  History of pancreatic disease or impaired pancreatic function (defined as the need to
             use pancreatic enzymes)

          -  Active liver disease or a 3-fold elevation of liver transaminases (ALT, AST)

          -  Active malignancy

          -  History of severe cardiovascular disease including acute coronary syndrome, stroke or
             transient ischemic neurologic disorder during previous 6 months, atrial fibrillation
             or other arrhythmia requiring chronic antiarrhythmic medication, chronic heart failure
             (New York Heart Association grade III/IV)

          -  History of alcohol abuse, defined as &gt;4 units of alcohol/day (32 g or 40 ml of 100%
             alcohol)

          -  History of allergy for GLP-1 receptor agonists or DPP-4 inhibitors

          -  Any disease that could interfere with study procedures (e.g. decreased mobility,
             mental incapacity)

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Haluzik, MD DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>3rd Department of Medicine, General University Hospital and Charles University 1st Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Martin Haluzik</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

